logo
Plus   Neg
Share
Email

Lipocine Inc. (LPCN) Sank To A New Low After Failing To Win FDA Panel Backing

Lipocine Inc. (LPCN) announced after the close Wednesday that its New Drug Application for its oral testosterone product candidate TLANDO has failed to win support from an advisory committee to FDA.

Lipocine gapped open sharply lower Thursday, but traded in a range for the majority of the session. The stock closed down by 1.59 at $1.87 with volume at over a 7-month high. Lipocine plunged to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT